In a recent abstract, patients who received prior blinatumomab were more likely to have dim CD19 on their leukemia cells by flow cytometry prior to CD19 CAR T cell therapy and were more likely to experience treatment failure [29], although this has not been observed with all CAR designs [30]. Here, CD19 is linked to leukemia.